New hope for hard-to-treat colorectal cancer: experimental combo enters late-stage trial
NCT ID NCT07361003
First seen Jan 29, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tests whether adding the experimental drug suvemcitug to standard chemotherapy (FTD/TPI) helps people with advanced colorectal cancer that has stopped responding to other treatments live longer. About 464 participants will receive either the combination or a placebo plus chemotherapy. The goal is to see if the new combination improves survival and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Harbin Medical University University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.